1、What the Data Tells Us:FCM Landscape Findings2Maternal anemia is one of the most significant contributors to global maternal mortality Role of Iron:Iron deficiency anemia(IDA)is the most common type of maternal anemia.Oral iron therapy is widely used as the first-line treatment,but it is often inade
2、quate for women(e.g.,poor absorption,gastrointestinal side effects,and the need for more rapid correction during the later stages of pregnancy).Intravenous(IV)iron therapy has emerged as an effective alternative,with newer formulations such as ferric carboxymaltose(FCM)demonstrating superior perform
3、ance.Despite such findings,FCM uptake in low-and middle-income countries has remained limited.Sources:WHO global anaemia estimates:Key Findings(2025);Anemia during pregnancy and adverse pregnancy outcomes(Frontiers,2025);An analysis of anemia and pregnancy-related maternal mortality(J.Nutrition,2001
4、)3The Gates Foundation funded a 15-country landscape to understand country interest in,and readiness to,introduce and scale FCM.ObjectiveKey Country ActivitiesTarget PopulationOutputsUnderstand current FCM market landscape,country interest in and readiness to introduce and scale FCM,and projected gr
5、owth of FCM demand over next 5 years.To support the accelerated nature of this landscape,six countries relied on desk review only,and nine conducted both desk review and stakeholder interviews.Desk review only:Ghana,Lesotho,Malawi,Niger,Uganda,ZimbabweDesk review&stakeholder interviews:Bangladesh,Bu
6、rkina Faso,Ethiopia,Kenya,Nigeria,Pakistan,Rwanda,Senegal,TanzaniaPregnant women in their 2nd or 3rd trimester with moderate to severe anemia,attending at least one ANC visit1)Individual country FCM market analyses,including country-specific enablers and barriers2)FCM demand forecast through 20313)c